meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
4
mHNSCC - L2 - PDL1 negative
2
mHNSCC - L2 - PDL1 positive
1
hepatocell cancer (HCC)
1
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
nivolumab plus epacadostat
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus 5FU plus platin
retifanlimab plus enoblituzumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
versus all
vs HER inhibitor
vs EGFR inhibitor
vs cetuximab based chemotherapy
vs cetuximab plus platin plus 5FU
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs pembrolizumab based treatment
vs pembrolizumab alone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network